GSK Vaccines is a world leader in innovation and the manufacture of vaccines. We pioneer advances in vaccines against preventable diseases, to help reduce the impact of disease on the world’s population.
Our scientific expertise helps us to provide a broad range of vaccines solutions, from antigens and adjuvants to manufacturing and supply. Our extensive network of alliances, with a range of more than 100 agreements with companies, consortia, governments, charities and academia, contributes significantly to this.
Every opportunity is important to us, and we foster capabilities within each alliance partnership to help both parties to succeed.
Why collaborate with us?
Fostering innovation with our alliance partners lies at the heart of our business model. We can offer our alliance partners significant expertise and experience. For example:
- We currently hold 26% of the global vaccines market with more than 30 marketed vaccines, which altogether provide vaccination solutions for paediatrics, adolescents, adults, the elderly and travellers. Most of our marketed vaccines are a product of collaborations.
- Our Business Development team provides the expertise for assessing, executing and managing collaborations to generate benefit for our alliance partners, the population and our business. We are dedicated to finding the best operating model for both alliance parties.
- The structures of our collaborations are individually tailored, providing flexiblity. We have agreements spanning from classical licensing to joint ventures, technology transfer to supply. Our alliances help improve access to essential vaccines by supporting the development of local research and manufacturing capabilities in developing countries or emerging economies.
- Our alliance partners’ interests are kept central through open communication, fast turnaround of opportunities, and decisions to collaborate, which are critical for an efficient partnering process.
- We have extensive experience and track record of working with alliance partners in emerging economies such as Brazil, Russia, Vietnam and Saudi Arabia, as well as advanced Asian economies such as Japan.
“Our collaboration with GSK Vaccines has been forward thinking from the outset and through strong mutual commitment and drive, it has enabled our adjuvant technology to be applied in innovative R&D for vaccine development. We view our alliance with GSK Vaccines as being unique and the overall management of our collaboration has been invaluable.” - Dr. Garo Armen, chairman and CEO from Agenus
Our areas of interest
GSK Vaccines’ interests in future collaborations are diverse and include both research and development of prophylactic and therapeutic vaccines, adjuvants and manufacturing technologies. Specifically we are interested in the following areas:
- fundamental and applied immunology
- new protective antigens
- new vaccine targets
- adjuvants
- antigen delivery
- vaccine delivery
- new assessment technologies and analytical tools
- new production process technologies
"Our alliance is a perfect example of a very effective partnership between a major pharmaceutical company and an academic institution with the ultimate goal to accelerate the production of highly effective vaccines to treat AD patients. Such collaboration is essential to find a cure for AD and other chronic diseases.”- Serge Rivest of CHUC Montreal, Laval University
Contact us
If you are interested in collaborating with us or would like more information, please email us at: vaccinespartnering@gsk.com